Stay Connected with ERT:
-
Recent Posts
- Improving Your Drug’s Value Proposition throughout the Product Lifecycle: How Optimized Clinical Outcomes Assessment (COA) Strategies Can Drive Commercialization Success
- Metrics Champion Consortium – Cardiopulmonary Performance Metrics Initiative
- The Importance of Inspiratory Capacity in COPD Clinical Trials
- CLEAR Study Update: A look inside the collaboration between ERT and UCLA
- Brief Report – Changes to the FDA Draft Guidance Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials
Archives
Monthly Archives: November 2011
Evaluation of the effect on Cardiac Repolarization (QTc Interval) of Cytotoxic Oncologic Drugs
Information Provided by Dr. Robert Kleiman, Chief Medical Officer & Vice President, Global Cardiology During the development of oncologic agents, there are many cardiovascular toxicities to consider. Oncologic agents may produce direct cardiac contractile depression, myocardial ischemia, alterations in blood pressure, myocarditis, cardiac tamponade, … Continue reading
Posted in Cardiac Safety, Clinical Research, Clinical Trials, FDA, Oncology
Leave a comment
